IXICO’s Post

Live-cell analysis of 3D models is revolutionizing our understanding of this devastating condition by providing more biologically relevant insights. In addition to better in-vitro models, improved assays and technologies that can capture the data generated by these models are vital to accelerate therapeutic developments for Alzheimer's Disease. Download this white paper to learn how live cell analysis of 2D and 3D models provides a better understanding of the mechanism of AD by addressing the limitations of traditional methods. Read now: https://ow.ly/kqnY50Q8T8b

🧠 Advancing Medical Research Through Software Innovation In a combined effort with PhD researchers, I am excited to announce the development of a new tool designed to help students and researchers quantify alveolar wall thickness in lung images. Normally just one cell thick, any abnormal thickening of these walls can signal serious conditions such as malignancies, COPD, or damage caused by COVID-19. By converting visual data into measurable insights, this tool enables more quantitative approach to analysis of complex lung morphology—providing support for research that aims to improve the understanding of the relationship between stress and cancer. #HealthcareTech #MedicalImaging #ResearchInnovation

Just in: Europe's latest clinical trials are breaking new ground! 🌍🔬 Exciting times for healthcare in Europe as new clinical trials are underway. These trials are not just about pushing the boundaries of medicine, but also about offering hope to patients waiting for breakthrough treatments. 📊 One UK-based trial is exploring a novel therapy for Alzheimer's, aiming to slow the disease's progression. This could be a game-changer for millions affected by this condition. In Germany, researchers are testing a new cancer drug, with early results showing promise in reducing tumour size. It's a ray of hope for those battling the disease. 🧬 Meanwhile, a pan-European study is focusing on personalised medicine, tailoring treatments to individual genetic profiles. This could revolutionise how we approach chronic illnesses. These trials are more than scientific endeavours; they're personal stories of perseverance and the quest for better health outcomes. 👉 Your thoughts on these developments? How do you see them shaping the future of healthcare? Drop a comment or get in touch to discuss the potential impact of these trials. #ClinicalTrials #HealthcareInnovation #EuropeanMedicine

Exciting advancements in blood-based biomarker testing are coming across as a game changer in comparison to the current tests which often miss early signs by an average of 2.8 years when it comes to diagnosing Alzheimer's disease. Innovation based on blood-based biomarker lead to earlier detection and better risk assessments, paving the way for more effective clinical trials. An excellent white paper to explore to dive deeper into the science behind this groundbreaking testing technique and its potential to transform Alzheimer's diagnosis.

📃Scientific paper: Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression Abstract: Objective To employ Artificial Intelligence to model, predict and simulate the amyotrophic lateral sclerosis (ALS) progression over time in terms of variable interactions, functional impairments, and survival. Methods We employed demographic and clinical variables, including functional scores and the utilisation of support interventions, of 3940 ALS patients from four Italian and two Israeli registers to develop a new approach based on Dynamic Bayesian Networks (DBNs) that models the ALS evolution over time, in two distinct scenarios of variable availability. The method allows to simulate patients’ disease trajectories and predict the probability of functional impairment and survival at different time points. Results DBNs explicitly represent the relationships between the variables and the pathways along which they influence the disease progression. Several notable inter-dependencies were identified and validated by comparison with literature. Moreover, the implemented tool allows the assessment of the effect of different markers on the disease course, reproducing the probabilistically expected clinical progressions. The tool shows high concordance in terms of predicted and real prognosis, assessed as time to functional impairments and survival (integral of the AU-ROC in the first 36 months between 0.80–0.93 and 0.84–0.89 for the two scenarios, respectively). Conclusions Provided only with measurements commonly collected during the first visit, our models can predict... Continued on ES/IODE ➡️ https://etcse.fr/6jIT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you. #amyotrophiclateralsclerosis #als #charcot

June is #Alzheimersandbrainawarenessmonth During this time of rapid evolution and discovery in Alzheimer’s disease, neuroimaging is expected to play a critical role in clinical practice. Accurate interpretation of different tracers and biomarkers to detect AD is crucial and can make all the difference in identifying people who would benefit from novel disease-modifying therapies. Our program on neuroimaging will guide you through: watch our webcast, download our flash multimedia guide, access articles and detect early signs of AD in our imaging interpretation activity. Available now at https://lnkd.in/egPx3TZS --- This activity is supported by an educational grant from Lilly. #alzheimersawareness #alzheimersdisease #neuroimaging #medicaleducation #continuingmedicaleducation #cme #independentmedicaleducation #ime #SpringerIME

🔍 Join Quibim for an informative webinar exploring the evolution of prostate cancer screening and the role of artificial intelligence (#AI) alongside clinical and imaging tests. The distinguished speakers will delve into the latest research, shedding light on advancements beyond PSA testing, including MRI-based assessments. Gain invaluable insights into predictive algorithms, patient advocacy, health economics, and ongoing clinical studies, paving the way for scalable and effective detection strategies. 🚀 REGISTER HERE: https://buff.ly/3T80cOt Expert speakers: Dr. Shonit Punwani Anna Nogué Infante David Bazaga #Healthcare #ProstateCancer #DiagnosticImaging #MedicalImaging #ClinicalImaging

Advancing Alzheimer's Clinical Trial Endpoints: Imaging Biomarkers, COA Challenges, Movement Measures, and CV Risk, Upcoming Webinar Hosted by Xtalks — PRBuzz.co — #pin this #free #webinar #learn about the critical #role of imaging biomarkers in characterizing #patient eligibility, #safety and #therapeutic efficacy in #Alzheimers #disease #AD clinical #trials Attendees will #gain insights into endpoint #collection for clinical outcome assessments

Advanced MRI and Precision Medicine in Rheumatic Diseases. Exciting developments in precision medicine and patient phenotyping are taking center stage in rheumatoid clinical trials. We're diving into how advanced MRI can bolster these strategies.  With the advancement of imaging technologies like Dynamic Contrast Enhanced (DCE)-MRI, we're uncovering new possibilities in predicting disease progression and treatment response. Our work here at IAG, IMAGE ANALYSIS GROUP suggests that integrating advanced MRI-based biomarkers into treatment strategies could lead to more personalized and effective therapies for RA and other rheumatic diseases. #PrecisionMedicine #RheumatologyResearch #AdvancedImaging #PatientCare #Biotech #Clinicaltrials #rheumatology #biomarkers If you have a #clinicaltrials which requires #medicalimaging support, let's talk: david.cattaneo@ia-grp.com